JCC 10 Year Anniversary

JCC 10 years buttonDear ECCO Members, dear Friends,

September 2017 is a special month to mark in ECCO’s agenda: The Journal of Crohn’s and Colitis (JCC) celebrates its 10 Year Anniversary. Ten years during which it has continuously moved forward to become a key international journal relied upon by healthcare professionals around the world who care for patients with Inflammatory Bowel Diseases (IBD). Thanks to a great effort between the JCC Editorial Team, publishing house staff and the ECCO Office, it has grown to be a pre-eminent journal chosen by top authors to publish their research articles, and a platform for all the important ECCO Papers (ECCO Guidelines, Consensus Statements, Topical Reviews, etc.).

With an Impact Factor for 2016 of 5.813, the JCC ranks highly among the gastroenterology and hepatology journals: 11th out of 79. What a journey since 2009, when the JCC received its first Impact Factor (0.812)! Over the years, the number of issues published has also increased, showing the journal's growing success, and an increasing number of articles have been submitted to and accepted for the JCC. The JCC has a number of other key distinguishing features that explain its achievement. To cite only one, it benefits from a timely review process for all submitted articles, such that currently initial editorial decisions to authors are, on average, provided after just 2 weeks.  

This tremendous success, however, is no cause for resting on our laurels: It is one thing for the JCC to be a leading journal in its field, and another for it to maintain its position and to continue evolving. All efforts are being made to make the JCC even more attractive. This will mainly be achieved by maintaining a high Impact Factor, providing an increasingly speedy peer review and editorial decision process, improving the quality of the production with the publisher and actively soliciting work from the best and most influential IBD experts worldwide. It will also be accomplished by continuing expansion globally: Thus, readers worldwide will turn more to the JCC as the most trusted source of information about IBD. We will continue to focus on expanding the global reach of the JCC for both authors and readers.

As Editor-in-Chief since February 2014, I am very proud of the JCC’s evolution and status. But success does not just happen by chance and I would like to warmly thank the eight Associate Editors and the 67 Editorial Board Members who throughout the calendar year devote their own time to reviewing the articles of their peers (over 1,000 articles were submitted in 2016). I would also like to address a special thank you to Miquel A. Gassull (JCC Editor-in-Chief from 2007 until 2014), and Eduard Cabré (his Assistant Editor). The JCC’s development and success would never have been possible without the tremendous foundation they put in place.

And I would like to thank you all, readers as well as submitters, for trusting the JCC with your work. The journey continues to provide you with the best IBD journal possible, meeting your needs and requests!

Sincerely yours,

Laurence J. Egan
JCC Editor-in-Chief


Highlights

  • September 2007: 1st Issue published 
  • 2010: Increased to publishing 6 issues per year 
  • 2010: Accepted into Medline
  • 2012: Increased to publishing 10 issues per year 
  • 2013: Increased to publishing monthly 
  • December 2015: Article-level metrics available, enabling authors to track the impact of their research 
  • June 2015: The JCC moved into the top quartile of the Gastroenterology & Hepatology category of the JCR
  • September 2017: 10th Anniversary issue

 

Key Metrics

  • Impact Factor 2016: 5.813
  • Five Year Impact Factor5.926
  • Over 5,000 citations of the JCC content contributed to the latest Impact Factor
  • Average monthly downloads exceed 50,000 (in 2016)
  • Over 600,000 downloads in 2016
  • Over 1,000 articles submitted in 2016
  • Readers in over 160 countries 
  • Papers published by authors from 64 different countries
  • 14 days from submission to first decision
  • 863 news stories about this content (by 138 unique news outlets in 15 countries)
  • 2,417 tweets about this content (by 967 unique tweeters in 55 countries)

Posted in Publications

JCC 10 most cited Original Articles

Authors

Title

Publication Year, Volume, Issue

Total Citations

Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G, De Hertogh G, Hoffman I, D'Hoore A,  Van Steen K, Geboes K, Penninckx F, Rutgeerts P Long-term outcome after infliximab for refractory Ulcerative Colitis 2008
Volume 2, Issue 3
 106
Gearry RB, Irving PM, Barrett JS, Nathan DM, Shepherd SJ, Gibson PR Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with Inflammatory Bowel Disease - a pilot study 2009
Volume 3, Issue 1
 90
Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, Gisbert JP, Gallardo-Valverde JM, Gonzalez-Galilea A, Naranjo-Rodriguez A, de Dios-Vega JF, Muntane J, Gomez-Camacho F Does fecal calprotectin predict relapse in patients with Crohn's Disease and Ulcerative Colitis? 2010
Volume 4, Issue 2
 74
Ghosh S, Mitchell R Impact of Inflammatory Bowel Disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey 2007
Volume 1, Issue 1
 70
Paraskevi A, Theodoropoulos G, Papaconstantinou I, Mantzaris G, Nikiteas N, Gazouli M Circulating MicroRNA in Inflammatory Bowel Disease 2012
Volume 6, Issue 9
 66
Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, Komarek A, Lukas M Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's Disease 2013
Volume 7, Issue 9
 59
Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S Increasing incidence of Clostridium difficile - associated diarrhea in Inflammatory Bowel Disease 2009
Volume 3, Issue 1
 52
 Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, Huang B, Lomax KG, Pollack PF Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3 years for adalimumab-treated patients with early Crohn's Disease 2013
Volume 7, Issue 3
 48
Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, Chowers Y, Lang A Detection of infliximab in breast milk of nursing mothers with Inflammatory Bowel Disease 2011
Volume 5, Issue 6
 42
Hansen TS, Jess T, Vind I, Elkjaer M, Nielsen MF, Gamborg M, Munkholm P Environmental factors in Inflammatory Bowel Disease: A case-control study based on a Danish inception cohort 2011
Volume 5, Issue 6
 41